Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Nelkarmi Is Now Approved for ALK-Positive Lung Cancer, but Not for People Whose Only ALK Drug Was Lorbrena

The FDA approved Nelkarmi (neladalkib) for ALK-positive lung cancer on November 17, 2026. It is for people whose cancer grew after Alecensa, their only ALK drug, or after 2 or more ALK drugs and chemotherapy. Who qualifies, what the trial showed, the liver warning and which ALK drugs have results after common earlier treatments.

A dark forest path dusted with snow splits into two directions under bare winter trees.

What can someone with ALK-positive lung cancer take once their ALK drug stops working? On November 17, 2026 the FDA gave a new answer for some of them by approving Nelkarmi (neladalkib), a once-daily pill from Nuvalent, now part of GSK.

Nelkarmi is approved for adults with advanced ALK-positive lung cancer whose only earlier ALK drug was Alecensa (alectinib), or who have taken 2 or more ALK drugs and platinum chemotherapy. People whose only ALK drug was Lorbrena (lorlatinib) do not fit either group on the label.

Who Can Take Nelkarmi (Neladalkib) Under Its FDA Label?

Nelkarmi's label covers adults with ALK-positive non-small cell lung cancer that is locally advanced or metastatic, in 2 groups defined by their earlier treatment for that advanced cancer. The first group took Alecensa as their only ALK inhibitor. The second took 2 or more ALK inhibitors and also platinum-based chemotherapy, which uses a drug such as cisplatin or carboplatin.

Those groups mirror the people in ALKOVE-1, the trial behind the approval. In its second group, 95% had taken lorlatinib, and 84% had taken both lorlatinib and alectinib, according to the label. That means many people whose cancer grew on Lorbrena are covered, as long as Lorbrena was not their only ALK drug and they have also had platinum chemotherapy.

Lorbrena is itself approved as a first treatment. Someone whose cancer grows on Lorbrena as their only ALK drug therefore falls outside both Nelkarmi groups, and so does someone whose only earlier ALK drug was Alunbrig or Ensacove.

“one of the hardest moments is learning that a treatment that had been working”

Kirk Smith, President of ALK Positive, in GSK's November 17, 2026 approval announcement

How Often Tumors Shrank on Each ALK Drug After Earlier Treatment

Reported results for a second or third ALK drug differ by which ALK drug people took before. None of the 7 approved ALK drugs has FDA-reviewed results for people whose only earlier ALK drug was Lorbrena.

How often tumors shrank on each ALK drug, grouped by the ALK drug taken before
Each band groups study results by the ALK drug or drugs people had taken before. Each bar is one drug's result in that group.
After Xalkori only
After Zykadia only
After Alecensa only
After Lorbrena only Nelkarmi is not approved for this group
No FDA-reviewed results for any ALK drug
After 2 or more ALK drugs

A tumor counts as shrinking when the measured tumors got at least 30% smaller in total on scans, under the standard RECIST rules. Bars in the same band come from different trials with different patients and methods, so they cannot be compared or used to rank the drugs. Sources are the clinical studies section of each drug's FDA prescribing information and, for Nelkarmi, the FDA's November 17, 2026 approval announcement. All were checked November 18, 2026.

The top band covers people whose only earlier ALK drug was Xalkori. Among 163 of them who took Zykadia, tumors shrank in 44%.

A hatched bar marks an exploratory subgroup, looked at inside a bigger trial rather than studied on its own. Lorbrena's 31% after Alecensa comes from only 13 people, and the likely true figure could sit anywhere from 9% to 61%.

The empty Lorbrena band is the gap this post is about. No ALK drug has FDA-reviewed results for people whose only earlier ALK drug was Lorbrena, and Nelkarmi is not approved for them. The same lack of results applies after Alunbrig alone.

Trial Friend drew this chart from the study results in the FDA prescribing information for 6 of the drugs and the FDA's approval announcement for Nelkarmi, read on November 18, 2026. A missing result does not mean a drug cannot be used, and choosing one for a particular person is a decision to make with an oncologist.

Ensacove is left out of the chart because it is approved only for people who have never taken an ALK inhibitor. Five others, from Xalkori to Lorbrena, are approved for metastatic ALK-positive lung cancer without naming a required earlier treatment. Xalkori, the oldest, has no FDA-reviewed results after another ALK drug.

Latest for ALK-Positive Lung Cancer

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Want the next ALK-Positive Lung Cancer update without checking back?

We email you when a new ALK-Positive Lung Cancer trial opens or an FDA decision comes out.

You'll get trial alerts and disease updates for ALK-Positive Lung Cancer, and you can turn either off anytime. We never share your email. Privacy policy

What Nelkarmi Did in the ALKOVE-1 Trial

In ALKOVE-1, tumors shrank in 49% of 67 people whose only earlier ALK drug was Alecensa. They shrank in 32% of 155 people who had taken 2 or more ALK drugs and platinum chemotherapy. About half of the responses in each group lasted 12 months or longer, according to the label.

Response rates were lower in people who had already taken Lorbrena, most of whom had also taken other ALK drugs. Nuvalent's early November 2025 trial data, before FDA review, covered 253 people who had taken at least 1 ALK drug, including some outside the 2 approved groups. Tumors shrank in 46% of the 63 who had never taken Lorbrena and in 26% of the 190 who had (Nuvalent, 2025).

The trial also measured tumors in the brain, where ALK-positive lung cancer often spreads. Among people with measurable brain tumors, those tumors shrank in 55% of 20 in the Alecensa group and 26% of 53 in the group with 2 or more earlier drugs.

Nelkarmi was designed to work against G1202R, a change in the ALK gene that lets the cancer escape earlier ALK drugs. A 2016 study of 103 repeat biopsies found G1202R became significantly more common after second-generation ALK drugs such as Alecensa (Gainor et al., 2016). In ALKOVE-1, tumors with G1202R shrank in 77% of 13 people in the Alecensa group and 71% of 35 in the other group.

ALKOVE-1 had no comparison group, so these response rates cannot be set against another drug. Alice Shaw of Dana-Farber, an ALKOVE-1 investigator, said in GSK's announcement that "balancing disease control and long-term tolerability remains a significant challenge."

Rick Meyer joined the neladalkib (NVL-655) trial after 5 earlier ALK drugs. In a 2025 ALK Positive interview he said "NVL655 has the least side effects of all the medications I've tried". His account is one person's experience, and the label's side effect rates come next.

Nelkarmi's Liver Warning and Other Label Warnings

Nelkarmi has no boxed warning, but liver injury is its most common serious problem. Liver side effects affected 56% of the 700 people in the label's safety data, and 25% had a severe or life-threatening liver event. The label calls for liver blood tests every 2 weeks for the first 2 months, then monthly.

The other label warnings cover kidney injury, eye problems in 14%, a rise in the muscle enzyme CPK in 28% and harm to an unborn baby. The label asks for nonhormonal birth control during treatment and for 2 weeks after, and says Nelkarmi's effect on hormonal birth control is unknown. It also asks men with partners who could become pregnant to use birth control for 2 weeks after, and advises against breastfeeding for 2 weeks after.

In the trial's lung cancer patients, muscle and bone pain (33%) and constipation (28%) were the most common side effects after liver changes. A changed sense of taste (25%), nerve tingling or numbness (23%) and tiredness (21%) came next. The dose is 150mg once a day, with or without food, swallowed whole. The label says to avoid taking Nelkarmi with strong or moderate CYP3A inhibitors or inducers, medicines that change how the body handles it.

Why Nelkarmi's Approval Is Accelerated, and What the ALKAZAR Trial Must Show

The FDA granted accelerated approval, meaning it approved Nelkarmi on tumor shrinkage and how long it lasted rather than on longer survival. The FDA requires Nuvalent to complete the ALKAZAR trial (NCT06765109), and continued approval may depend on confirming a benefit. The FDA's list of ongoing accelerated approvals gives a projected completion date of April 30, 2030.

ALKAZAR tests a different group from the one the approval covers. It compares Nelkarmi with Alecensa in about 450 people who have never taken an ALK inhibitor. Of its 23 US sites, 22 were recruiting when Trial Friend checked ClinicalTrials.gov on November 18, 2026.

Getting Nelkarmi, and Where People After Lorbrena Can Look Next

Nuvalent's ordering sheet says Nelkarmi is approved but not yet available for purchase or shipment. Nuvalent Patient Support helps with insurance coverage, costs and starting treatment, though its Nelkarmi page still read "Coming Soon" on November 18. No price had been published when this was checked.

For people whose cancer grew on Lorbrena alone, studies are the main route to new drugs. Astellas is testing gilteritinib (NCT07140016) at 9 US sites, and it accepts people who had lorlatinib among their earlier ALK drugs. TRIANA's TRI-611 study (NCT07491497) is recruiting at 14 US sites, but it requires that lorlatinib was not the first ALK drug. The ALK-positive lung cancer page lists open studies and their locations.

Repeat testing shapes each of these choices. The 2016 biopsy study described repeat biopsies and gene testing after the cancer grows as important for choosing what comes next (Gainor et al., 2016). Questions worth bringing to an oncologist include whether a new biopsy or blood test has been done and which resistance changes it found.

Michael Hu was diagnosed at 43 in 2022. In a June 2026 ALK Positive profile he said "I've had to switch treatments about once a year". For people on that cycle, Nelkarmi adds an option at one turn of the path, while the Lorbrena-only branch still waits for its own label.

Nelkarmi and ALK-Positive Lung Cancer in Brief

Is Nelkarmi FDA approved?

Yes, the FDA granted accelerated approval to Nelkarmi (neladalkib) on November 17, 2026 for advanced ALK-positive non-small cell lung cancer. It covers adults whose only earlier ALK drug was Alecensa, or who have had 2 or more ALK drugs and platinum chemotherapy. It also holds breakthrough therapy and orphan drug designations, according to the FDA.

Can I take Nelkarmi after Lorbrena?

Only if Lorbrena was not your only ALK drug and you have also had platinum chemotherapy, under the label. In ALKOVE-1, 95% of the group with 2 or more earlier ALK drugs had taken lorlatinib. Someone whose only earlier ALK drug was Lorbrena is outside both label groups.

What is the ALK G1202R mutation?

G1202R is a change in the ALK gene that can let lung cancer grow despite earlier ALK drugs. A 2016 study found it more often after second-generation drugs such as Alecensa. In ALKOVE-1, tumors with G1202R shrank in 77% of 13 people after Alecensa alone and 71% of 35 after 2 or more ALK drugs.

How is Nelkarmi taken?

Nelkarmi is a 150mg tablet taken by mouth once a day, with or without food, swallowed whole and not split or crushed. A dose missed by more than 12 hours is skipped, according to the label, and doses can be lowered to 100mg or 50mg for side effects.

When will Nelkarmi be available?

Nuvalent had not announced a shipping date as of November 18, 2026, and its ordering sheet said the drug was not yet available for purchase. Its in-network specialty pharmacy is Biologics by McKesson, and Nuvalent Patient Support is at (844) 688-5333.

Does Nelkarmi work for ALK-positive lung cancer in the brain?

In ALKOVE-1, brain tumors shrank in 55% of 20 people whose only earlier ALK drug was Alecensa and in 26% of 53 people with 2 or more earlier ALK drugs. The trial had no comparison group, so the results show activity rather than a ranking against other drugs.

Know someone this would help?
Get the next ALK-Positive Lung Cancer update by email

One email when ALK-Positive Lung Cancer trials change or an FDA decision lands. No newsletter, no spam.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Sources

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
Nuvalent, Inc. · 2025-11-17
NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information
Nuvalent, Inc. · 2026-11
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer
U.S. Food and Drug Administration · 2026-11-17
Ongoing | Cancer Accelerated Approvals
U.S. Food and Drug Administration · 2026-11-17
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
GSK plc · 2026-11-17
Ordering Information for NELKARMI
Nuvalent, Inc. · 2026-11
Nuvalent Patient Support, Nelkarmi
Nuvalent, Inc. · 2026-11-18
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR)
ClinicalTrials.gov · 2026-11-18
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
ClinicalTrials.gov · 2026-11-18
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
ClinicalTrials.gov · 2026-11-18
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov · 2026-11-18
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Cancer Discovery · 2016-10
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Cancer Discovery · 2024-12-02
Patient Spotlight: Rick Meyer
ALK Positive, Inc. · 2025-07-11
Meet Michael Hu: Medical Astronaut
ALK Positive, Inc. · 2026-06-17
XALKORI (crizotinib) prescribing information
Pfizer, via DailyMed
ZYKADIA (ceritinib) prescribing information
Novartis, via DailyMed
ALECENSA (alectinib) prescribing information
Genentech, via DailyMed
ALUNBRIG (brigatinib) prescribing information
Takeda, via DailyMed
LORBRENA (lorlatinib) prescribing information
Pfizer, via DailyMed
ENSACOVE (ensartinib) prescribing information
Xcovery, via DailyMed
TaggedFDA DecisionsALK-Positive Lung CancerNelkarmiNeladalkib

More on Trial Friend